颅底和脊索瘤的外科治疗:一个病例系列并综合文献回顾

Q3 Medicine
Sarah Lee , Nahom Teferi , Juan Vivanco-Suarez , Ajmain Chowdhury , Stephen Glennon , Kyle Kato , Tyson Matern , Kathryn L. Eschbacher , Michael Petronek , Patrick Hitchon
{"title":"颅底和脊索瘤的外科治疗:一个病例系列并综合文献回顾","authors":"Sarah Lee ,&nbsp;Nahom Teferi ,&nbsp;Juan Vivanco-Suarez ,&nbsp;Ajmain Chowdhury ,&nbsp;Stephen Glennon ,&nbsp;Kyle Kato ,&nbsp;Tyson Matern ,&nbsp;Kathryn L. Eschbacher ,&nbsp;Michael Petronek ,&nbsp;Patrick Hitchon","doi":"10.1016/j.xnsj.2024.100569","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Chordomas are rare, slow growing, locally aggressive malignant bone tumors that arise from remnants of the embryonic notochord with variable presenting symptoms depending on tumor location.</div></div><div><h3>Methods</h3><div>All patients with craniospinal chordoma managed at our institution between 1982 and 2023 were retrospectively reviewed. Demographics, tumor characteristics, clinical course and treatment, and long-term neurological and survival outcomes were collected. Adjuvant radiotherapy (RT) was stratified into standard dose fractionated radiotherapy (standard XRT) for doses of 50 to 60 Gy at 1.8 Gy fractions or high dose hyperfractionated stereotactic radiotherapy (HD-FSRT) for doses of 60 to 81 Gy at 1.2-1.5 Gy fractions per treatment. Descriptive statistics, univariate analysis, Log-rank test, and Kaplan-Meier survival analysis were performed.</div></div><div><h3>Results</h3><div>A total of 37 patients were included in our cohort (mean age 46.0 ± 20.8 years; 22 male). Clival chordomas accounted for the majority of patients (56.8%), followed by vertebral (27%) and sacral (10.8%) chordomas. Thirty-five patients (94.6%) underwent gross total resection (GTR) or subtotal resection (STR), and 2 patients underwent excisional biopsy only. Postoperatively, functional status trended towards improvement (KPS: Preop- 80 [range 40–100] vs. Post op- 90 [60–100], p = .0911) and all patients either maintained or improved their neurological function. Median overall survival (OS) after diagnosis was 16.5 years. Age &lt; 65, clival tumor location, post-operative Frankel grade E, and administration of adjuvant RT following initial STR significantly improved OS. OS of GTR patients was not significantly affected by adjuvant RT treatment.</div></div><div><h3>Conclusions</h3><div>Our results show the best long-term survival outcomes for chordoma patients undergoing GTR of tumor tissue. Higher postoperative neurological function was significantly associated with OS, highlighting the importance of maximal but safe total tumor resection. Moreover, adjuvant RT improved long-term survival for patients that underwent STR but had no effect on survival outcomes for patients that underwent GTR.</div></div>","PeriodicalId":34622,"journal":{"name":"North American Spine Society Journal","volume":"20 ","pages":"Article 100569"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Surgical management of skull base and spinal chordomas: A case series with comprehensive review of the literature\",\"authors\":\"Sarah Lee ,&nbsp;Nahom Teferi ,&nbsp;Juan Vivanco-Suarez ,&nbsp;Ajmain Chowdhury ,&nbsp;Stephen Glennon ,&nbsp;Kyle Kato ,&nbsp;Tyson Matern ,&nbsp;Kathryn L. Eschbacher ,&nbsp;Michael Petronek ,&nbsp;Patrick Hitchon\",\"doi\":\"10.1016/j.xnsj.2024.100569\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Chordomas are rare, slow growing, locally aggressive malignant bone tumors that arise from remnants of the embryonic notochord with variable presenting symptoms depending on tumor location.</div></div><div><h3>Methods</h3><div>All patients with craniospinal chordoma managed at our institution between 1982 and 2023 were retrospectively reviewed. Demographics, tumor characteristics, clinical course and treatment, and long-term neurological and survival outcomes were collected. Adjuvant radiotherapy (RT) was stratified into standard dose fractionated radiotherapy (standard XRT) for doses of 50 to 60 Gy at 1.8 Gy fractions or high dose hyperfractionated stereotactic radiotherapy (HD-FSRT) for doses of 60 to 81 Gy at 1.2-1.5 Gy fractions per treatment. Descriptive statistics, univariate analysis, Log-rank test, and Kaplan-Meier survival analysis were performed.</div></div><div><h3>Results</h3><div>A total of 37 patients were included in our cohort (mean age 46.0 ± 20.8 years; 22 male). Clival chordomas accounted for the majority of patients (56.8%), followed by vertebral (27%) and sacral (10.8%) chordomas. Thirty-five patients (94.6%) underwent gross total resection (GTR) or subtotal resection (STR), and 2 patients underwent excisional biopsy only. Postoperatively, functional status trended towards improvement (KPS: Preop- 80 [range 40–100] vs. Post op- 90 [60–100], p = .0911) and all patients either maintained or improved their neurological function. Median overall survival (OS) after diagnosis was 16.5 years. Age &lt; 65, clival tumor location, post-operative Frankel grade E, and administration of adjuvant RT following initial STR significantly improved OS. OS of GTR patients was not significantly affected by adjuvant RT treatment.</div></div><div><h3>Conclusions</h3><div>Our results show the best long-term survival outcomes for chordoma patients undergoing GTR of tumor tissue. Higher postoperative neurological function was significantly associated with OS, highlighting the importance of maximal but safe total tumor resection. Moreover, adjuvant RT improved long-term survival for patients that underwent STR but had no effect on survival outcomes for patients that underwent GTR.</div></div>\",\"PeriodicalId\":34622,\"journal\":{\"name\":\"North American Spine Society Journal\",\"volume\":\"20 \",\"pages\":\"Article 100569\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"North American Spine Society Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666548424002622\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"North American Spine Society Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666548424002622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

脊索瘤是一种罕见的、生长缓慢的、局部侵袭性的恶性骨肿瘤,起源于胚胎脊索的残余,随肿瘤位置的不同而有不同的症状。方法回顾性分析我院1982 ~ 2023年间收治的所有颅脊索瘤患者。收集人口统计学、肿瘤特征、临床病程和治疗、长期神经学和生存结果。辅助放疗(RT)分为标准剂量分割放疗(standard XRT)和高剂量超分割立体定向放疗(HD-FSRT),分别为50 - 60 Gy、1.8 Gy和60 - 81 Gy、1.2-1.5 Gy。进行描述性统计、单因素分析、Log-rank检验和Kaplan-Meier生存分析。结果共纳入37例患者(平均年龄46.0±20.8岁;22岁男性)。以斜坡脊索瘤为主(56.8%),其次为椎脊索瘤(27%)和骶脊索瘤(10.8%)。35例(94.6%)患者行全切除(GTR)或次全切除(STR), 2例仅行切除活检。术后功能状态趋于改善(KPS:术前- 80[范围40-100]vs术后- 90 [60-100],p = 0.0911),所有患者的神经功能均维持或改善。诊断后的中位总生存期(OS)为16.5年。年龄& lt;65,斜坡肿瘤位置,术后Frankel分级E,以及初始STR后给予辅助RT显著改善OS。辅助RT治疗对GTR患者的OS无显著影响。结论sour结果显示脊索瘤患者行肿瘤组织GTR的远期生存效果最好。较高的术后神经功能与OS显著相关,强调了最大但安全的肿瘤全切除术的重要性。此外,辅助RT改善了STR患者的长期生存,但对GTR患者的生存结果没有影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Surgical management of skull base and spinal chordomas: A case series with comprehensive review of the literature

Background

Chordomas are rare, slow growing, locally aggressive malignant bone tumors that arise from remnants of the embryonic notochord with variable presenting symptoms depending on tumor location.

Methods

All patients with craniospinal chordoma managed at our institution between 1982 and 2023 were retrospectively reviewed. Demographics, tumor characteristics, clinical course and treatment, and long-term neurological and survival outcomes were collected. Adjuvant radiotherapy (RT) was stratified into standard dose fractionated radiotherapy (standard XRT) for doses of 50 to 60 Gy at 1.8 Gy fractions or high dose hyperfractionated stereotactic radiotherapy (HD-FSRT) for doses of 60 to 81 Gy at 1.2-1.5 Gy fractions per treatment. Descriptive statistics, univariate analysis, Log-rank test, and Kaplan-Meier survival analysis were performed.

Results

A total of 37 patients were included in our cohort (mean age 46.0 ± 20.8 years; 22 male). Clival chordomas accounted for the majority of patients (56.8%), followed by vertebral (27%) and sacral (10.8%) chordomas. Thirty-five patients (94.6%) underwent gross total resection (GTR) or subtotal resection (STR), and 2 patients underwent excisional biopsy only. Postoperatively, functional status trended towards improvement (KPS: Preop- 80 [range 40–100] vs. Post op- 90 [60–100], p = .0911) and all patients either maintained or improved their neurological function. Median overall survival (OS) after diagnosis was 16.5 years. Age < 65, clival tumor location, post-operative Frankel grade E, and administration of adjuvant RT following initial STR significantly improved OS. OS of GTR patients was not significantly affected by adjuvant RT treatment.

Conclusions

Our results show the best long-term survival outcomes for chordoma patients undergoing GTR of tumor tissue. Higher postoperative neurological function was significantly associated with OS, highlighting the importance of maximal but safe total tumor resection. Moreover, adjuvant RT improved long-term survival for patients that underwent STR but had no effect on survival outcomes for patients that underwent GTR.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
71
审稿时长
48 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信